Bayer’s AskBio gene therapy unit has started recruiting patients into a phase 2 trial of its AB-1002 candidate for congestive heart failure (CHF), buoyed by encouraging data from a first-in-human ...
Bayer’s AskBio unit has reported the first clinical data for its congestive heart failure gene therapy, showing preliminary signs of efficacy with no serious adverse events linked to the treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback